Competitive Rivalry

Generic-drug competition is highly fragmented and price-led, so Teva’s scale helps but does not prevent rapid erosion versus larger global peers.

In specialty and biosimilar categories, Teva faces branded and biosimilar rivals with similar regulatory pathways, limiting sustained margin differentiation versus peers.

Patent expiries and tender-driven pricing in key markets compress industry economics, and Teva’s mix remains exposed to the same cyclical price resets as peers.

Threat Of New Entrants

Regulatory approval, bioequivalence testing, and manufacturing compliance create meaningful entry barriers, which protect incumbent scale players like Teva versus smaller entrants.

Capital intensity and quality-system requirements raise the cost of entry in complex injectables and biosimilars, making new competition slower to emerge than in simple generics.

However, large global generic manufacturers and regional specialists can still enter selected molecules, so barriers are real but not absolute versus established peers.

Bargaining Power Of Suppliers

Active pharmaceutical ingredients and specialized contract manufacturing inputs are concentrated in parts of the supply chain, which can pressure Teva’s gross margin similarly to peers.

Teva’s broad product portfolio provides some procurement leverage, but commodity API dependence limits the ability to fully pass through cost inflation versus larger peers.

Regulatory qualification of alternate suppliers is slow, so disruptions can temporarily raise input costs and constrain flexibility across the industry.

Bargaining Power Of Buyers

Large wholesalers, pharmacy benefit managers, and national health systems negotiate aggressively, leaving Teva with limited pricing power in core generic channels versus peers.

Tender-based purchasing and formulary concentration make volume retention dependent on price concessions, which structurally compresses margins across the industry.

In the U.S. and Europe, buyer consolidation keeps reimbursement pressure high, and Teva’s scale does not materially offset this structural discounting.

Threat Of Substitutes

For many molecules, therapeutic substitution to lower-cost generics is already embedded in the market, so Teva benefits from substitution rather than being protected from it.

Branded therapies, biosimilars, and alternative dosage forms can divert demand from specific products, but the effect is uneven and molecule-specific versus peers.

In specialty areas, physician and payer preferences can shift share toward differentiated alternatives, limiting Teva’s ability to sustain premium pricing.

Overall Score

Teva operates in an industry with high buyer power and intense price competition, while entry barriers and scale provide only partial insulation versus global peers.